In fact, Bao et al.25revealed that overexpression of eIF5A2 reduced doxorubicin sensitivity in colon cancer cells, suggesting that inhibition of eIF5A2 expression may be a potential target to revert resistance in colorectal cancer therapy. Here, EIF5A2 is linked to colonic neoplasm.